Abstract 99P
Background
In the era of immunotherapy, whether removal of tumor -draining lymph nodes (TDLNs) should be removed as the traditional surgery way or should be surgical method or preserved preservation remains controversialis still unknown.
Methods
In this study, 42 mismatch repair deficient (dMMR) and 42 mismatch repairs proficient (pMMR) colon cancer patients were enrolled. Imaging data and single-cell RNA sequencing of tumor-draining lymph nodes were also investigated for comprehensive profiling of the microenvironment. The cells of tumor-draining lymph nodes in patients with dMMR colon cancer after neoadjuvant immunotherapy were analyzed to determine their T-cell phenotype.
Results
No significant differences in presurgical clinical characteristics were detected between the dMMR and pMMR groups. However, greater disease-free survival was observed in dMMR patients than in pMMR patients (p =0.02). Approximately 52.4% of patients with dMMR treated with a whole regimen of Pd-1 blockade (dMMR+Pd-1) achieved a pathological complete response (pCR). Eight of the 42 dMMR patients experienced bowel obstruction during treatment. The single-cell transcriptome revealed enrichment of naïve-like CD8+ T cells in the TDLNs of dMMR responders. In addition, we observed that macrophages in dMMR responder TDLNs were polarized toward the M1 phenotype. The altered microenvironment was accompanied by the complete eradication of malignant cells in TDLNs upon Pd-1 blockade treatment.
Conclusions
To maintain a durable response to ICIs, TDLN preservation could be considered a potential reservoir of memory T cells to sustain ICI responses and reduce the risk of relapse and progression in dMMR+Pd-1 blockade colon cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Sun Yat-sen University Cancer Center, Chinese Society of Clinical Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract